AbbVie raises profit guidance following strong Q3 results

AbbVie Skyrizi Rinvoq pharmaceutical earnings immunology drugs

AbbVie reported third-quarter revenue of $17.4 billion, a 10.3% increase year over year, surpassing Wall Street estimates. The pharmaceutical company reported adjusted earnings per share of $3.82, more than doubling the $1.86 reported in the same period last year.

Growth was primarily driven by the immunology portfolio, led by Skyrizi, which generated $5.78 billion in revenue, and Rinvoq, which brought in $2.71 billion. These newer therapies are successfully offsetting the revenue decline from Humira, which saw sales drop 31.2% following the loss of US patent exclusivity in 2023. The neuroscience division also saw significant growth, with revenue rising 19% to $3.39 billion, supported by Botox Therapeutic and Vraylar.

Following these results, AbbVie raised its full-year 2026 adjusted earnings guidance to a range of $13.95 to $13.99 per share. Additionally, the company announced a 5.2% increase in its quarterly dividend, with higher payments scheduled to begin in February 2027.

Entities

AbbVie · AbbVie Inc. · Apogee Therapeutics · Humira · Rinvoq · Robert A. Michael · Skyrizi

Claims

What the coverage asserts, and how many sources carry each claim.

[● 3 SOURCES] AbbVie reported third-quarter revenue of $17.4 billion. bitfinanzas.com · srnnews.com
[● 2 SOURCES] Rinvoq generated $2.71 billion in revenue during the quarter. bitfinanzas.com · srnnews.com
[○ 1 SOURCE] Humira sales were $683 million for the quarter. bitfinanzas.com
[○ 1 SOURCE] The neuroscience division revenue increased by 19%. srnnews.com
[● 3 SOURCES] AbbVie's adjusted profit per share for the quarter was $3.82. bitfinanzas.com · srnnews.com
[● 3 SOURCES] The company raised its annual adjusted profit forecast to a range of $13.95 to $13.99 per share. bitfinanzas.com · srnnews.com
[● 2 SOURCES] Skyrizi recorded quarterly sales of $5.78 billion. bitfinanzas.com · srnnews.com
[● 2 SOURCES] AbbVie completed a $10.9 billion acquisition of Apogee Therapeutics in June. srnnews.com